)
Visual21 Nov 2025
Data center suppliers
VistaGen Therapeutics (VTGN) investor relations material
VistaGen Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Nov, 2025
Executive summary
Achieved a major milestone with the last patient completing the randomized double-blind portion of the PALISADE 3 phase III trial for fasedienol in social anxiety disorder; top-line results expected by year-end 2025.
PALISADE 4 phase III trial remains on track for top-line results in the first half of 2026, both using a public speaking challenge design and primary efficacy endpoint as in PALISADE 2.
Advancing a broader neuroscience pipeline, including Itruvone for major depressive disorder and PH80 for menopausal hot flashes, with five clinical-stage product candidates.
Welcomed Paul Edick to the board, bringing significant experience in FDA approvals and commercial launches.
Company has not achieved revenue-generating status from product sales and expects continued operating losses as development progresses.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $77.2 million as of September 30, 2025.
Net loss was $19.4 million for the quarter and $34.5 million for the six months ended September 30, 2025, compared to $13.0 million and $23.7 million for the same periods in 2024.
Research and development expenses increased to $15.9 million for the quarter and $27.7 million for the six months, mainly due to expanded clinical activity for fasedienol.
General and administrative expenses were $4.4 million for the quarter and $8.7 million for the six months.
Revenue was $0.3 million for the quarter and $0.5 million for the six months, primarily from the AffaMed license agreement.
Outlook and guidance
Top-line results from PALISADE 3 to be released before the end of calendar year 2025; PALISADE 4 top-line results anticipated in the first half of 2026.
NDA submission for fasedienol possible around mid-2026 if PALISADE 3 is positive and all required studies are completed.
Expects research and development expenses to increase as clinical programs advance and headcount grows.
Uncertainty exists regarding whether current cash resources will fund operations beyond twelve months from the financial statement issuance date.
Plans to seek additional capital through equity, debt, grants, or strategic partnerships as needed.
Readiness for fasedienol self-commercialization
Impact of PALISADE-3 not replicating PALISADE-2
Implications of OLE usage patterns for market
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next VistaGen Therapeutics earnings date
Q3 202612 Feb, 2026
Next VistaGen Therapeutics earnings date
Q3 202612 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's pipeline includes drug candidates designed to address mental health conditions such as anxiety, depression, and social anxiety disorder. VistaGen’s lead programs aim to provide rapid-acting treatments that target specific CNS pathways, offering potential alternatives to traditional therapies. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage